China and India to be world leaders of innovation
China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.
China and India will become the world leaders in innovation during the next decade, according to an international survey released by AstraZeneca.
The survey comprised 6000 respondents across six countries (China, India, Japan, Sweden, the UK and the US), with the overall consensus being that China will be the most innovative by 2020, followed by India. The two current leaders in innovation, the US and Japan, will be relegated to third and fourth respectively by 2020.
According to AstraZeneca, there is a strong sense of optimism amongst respondents in the developing nations of China and India about the ability of their nations to prosper through innovation. “People in both India and China strongly believe that their country will be the most innovative in 2020. This is most striking in India, where respondents have shown a remarkable self-confidence for their innovative climate, both now and in the future,” said the survey. In India, 16% of respondents already believe that their country is the most innovative in the world and 56% believe this will be the case by 2020.
This optimism is a stark contrast to the views of respondents in developed western economies; in the UK for example, two-thirds of respondents believe that the country is not as innovative as it used to be, and only 5% believe that the UK will be the most innovative country by 2020. Respondents in Japan and the US also believe that their country is not as innovative as it once was.
Respondents were also asked about the importance of specific innovations over the past century. In general, respondents rated the internet, computers and electricity as the most important innovations, but people in Sweden, the UK and the US also placed equal importance on innovation in vaccines and antibiotics.
According to David Brennan, Chief Executive of AstraZeneca, the survey offers a “fascinating perspective into what innovation means to people from different parts of the world”. He also added: “I am convinced that it’s combining the best skills and talents from around the world that drives the greatest innovations – I see much stronger results coming from those countries and organizations that make strong connections across boundaries, and share the best ideas, breaking new ground along the way.”
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
